Clovis Oncology names new board chair

BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has appointed Ginger L. Graham as chair of the company’s board of directors. She succeeds M. James Barrett, who retired.

“I am very pleased to announce that Ginger Graham is assuming the role of our Board Chair at Clovis Oncology,” Clovis president and CEO Patrick Mahaffy said in a prepared statement. “As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a health-care executive to her elevated role as Board Chair. I would also like to thank Jim Barrett for his service as our Board Chair since we started the Company 10 years ago. We wish him a very happy and hopefully relaxed retirement.”

Graham has served on Clovis’ board since 2013. She is the former president and CEO of Amylin Pharmaceuticals Inc., a San Diego-based biopharmaceutical company that focused on diabetes.

Boulder-based Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents.

BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has appointed Ginger L. Graham as chair of the company’s board of directors. She succeeds M. James Barrett, who retired.

“I am very pleased to announce that Ginger Graham is assuming the role of our Board Chair at Clovis Oncology,” Clovis president and CEO Patrick Mahaffy said in a prepared statement. “As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a health-care executive to her elevated role as Board Chair. I would also like to thank Jim Barrett for his service as our Board Chair since we started the Company 10 years ago. We wish him a very happy and hopefully relaxed retirement.”

Graham has served on Clovis’ board since 2013. She is the former president and CEO of Amylin Pharmaceuticals Inc., a San Diego-based biopharmaceutical company that focused on diabetes.

Boulder-based Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents.